Xencor's reliance on unpredictable milestone-based revenue, which saw a 59.7% contraction in 2025Q4, creates significant volatility that complicates long-term financial forecasting. While the company maintains high gross margins often exceeding 90%, these are ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.29+63.8% vs -$0.80 | $51M+171.2% vs $19M |
Q2 2026 May 6, 2026 | -$1.71-163.1% vs -$0.65 | $5M-83.8% vs $28M |
Q1 2026 Feb 25, 2026 | -$0.09+85.9% vs -$0.64 | $28M-5.8% vs $30M |
Q4 2025 Nov 5, 2025 | -$0.08+88.9% vs -$0.72 | $21M-29.9% vs $30M |
Bank of New York Mellon Corp acquired a new position in shares of Xencor, Inc. (NASDAQ: XNCR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 410,769 shares of the biopharmaceutical company's stock, valued at approximately $6,613,000. Bank
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.A live webcast of the presentation will be available under “Events & Presentations” in the Investors section of Xencor's website located at w.
Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $23.47 and last traded at $23.12, with a volume of 962153 shares trading hands. The stock had previously closed at $23.34. Analyst Upgrades and Downgrades Several research analysts recently weighed
Xencor (XNCR) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.41 per share a year ago.
Benchmark XNCR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Xencor, Inc. (XNCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $24.26 | $1.8B | -19.56 | 13.65% | -73.2% | -14.04% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $3.80 | $241.54M | -3.22 | 0.78% | -8.7% | -31.27% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $42.13 | $7.07B | 29.46 | -5.25% | 3.96% | 3.72% | — | |
| $27.50 | $2.02B | -25.46 | 38.87% | -138685.11% | -222.5% | — |
Xencor, Inc. (XNCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Xencor, Inc. (XNCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 29, 2026·SEC
Jun 18, 2026·SEC
Get notified when XNCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Xencor, Inc. (XNCR) stock FAQ — growth, dividends, profitability & financials explained
Xencor, Inc. (XNCR) reported $105.0M in revenue for fiscal year 2025. This represents a 1433% increase from $6.8M in 2011.
Xencor, Inc. (XNCR) grew revenue by 13.7% over the past year. This is steady growth.
Xencor, Inc. (XNCR) reported a net loss of $163.3M for fiscal year 2025.
Xencor, Inc. (XNCR) has a return on equity (ROE) of -14.0%. Negative ROE indicates the company is unprofitable.
Xencor, Inc. (XNCR) had negative free cash flow of $276.5M in fiscal year 2025, likely due to heavy capital investments.
